Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis.
Roy M FleischmannJingyu LiuJulie ZhuOscar G SeguradoDaniel E FurstPublished in: Arthritis care & research (2021)
Our results suggest overall MBDA scores are not sufficiently responsive for assessing RA disease activity after RCI therapy. These findings are consistent with those seen with other RA drugs and, although they are from a clinical trial, suggest the MBDA should not be a preferred disease activity measure in clinical practice.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- clinical trial
- juvenile idiopathic arthritis
- clinical practice
- interstitial lung disease
- randomized controlled trial
- drug delivery
- cancer therapy
- study protocol
- systemic sclerosis
- open label
- phase ii
- phase iii